Rich Pharmaceuticals (RCHA) 10-K 17 Sep 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2015	Jul. 14, 2015	Sep. 30, 2014
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	10-K
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 12,000,000
Entity Common Stock, Shares Outstanding		3,097,091,736
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Current Assets
Cash and equivalents	$ 15,892	$ 12,387
Prepaid expenses	7,578	1,561
Total Current Assets	23,470	13,948
Property and equipment, net	788	1,261
TOTAL ASSETS	24,258	15,209
Current Liabilities
Accounts payable	910,272	180,672
Accrued expenses	200,891	451,290
Due to related parties	6,067	36,000
Stock deposits	0	147,050
Convertible notes payable, net of debt discount	402,131	37,500
Derivative liabilities	139,983	0
Total Current Liabilities	1,659,344	852,512
Long-term Liabilities
Convertible notes payable, net of debt discount	6,080	0
Derivative liabilities	77,775	0
Total Long-term Liabilities	83,855	0
Total Liabilities	1,743,199	852,512
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $.001 par value, 37,503,000,000 shares authorized, 1,541,083,957 and 414,411,438 shares issued and outstanding, respectively	1,541,083	414,411
Additional paid-in capital	4,168,956	2,043,690
Accumulated deficit	(7,434,980)	(3,301,404)
Total Stockholders Deficit	(1,718,941)	(837,303)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 24,258	$ 15,209

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) None in scaling factor is -9223372036854775296	Mar. 31, 2015	Mar. 31, 2014
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000
Common Stock, Issued	1,541,083,957	414,411,438
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000
Accumulated Amortization of intangible assets

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0
OPERATING EXPENSES
Consulting expenses	200,925	335,000
Office expenses	97,821	39,569
Depreciation expense	473	158
Wages and taxes	727,458	291,358
Professional fees	1,339,623	115,304
Regulatory fees	52,496	37,591
Research and development	165,371	123,802
Stock-based compensation	866,128	1,869,273
Impairment of intangible asset	82,120	168,973
Travel, meals and entertainment	74,010	23,567
TOTAL OPERATING EXPENSES	3,606,425	3,004,595
LOSS FROM OPERATIONS	(3,606,425)	(3,004,595)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(504,269)	0
Change in value of derivative liability	1,867,621	0
Derivative expense	(1,809,914)	0
Forgiveness of debt	6,009	0
Interest expense	(56,531)	(342)
Interest expense, related party	(67)	0
Loss on share issuance	30,000	0
Other Income Total	(527,151)	(342)
LOSS BEFORE PROVISION FOR INCOME TAXES	(4,133,576)	(3,004,937)
PROVISION FOR INCOME TAXES	0	0
NET LOSS	$ (4,133,576)	$ (3,004,937)
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.01)	$ 0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	633,180,343	615,222,893

Shareholders Equity

Shareholders Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit During the Development Stage	Total
Beginning balance, shares at Mar. 31, 2013		1,093,837,500
Beginning balance, amount at Mar. 31, 2013		$ 2,625	$ 49,875	$ (81,930)	$ (29,430)
Stock issued for intangible assets, shares	6,000,000	82,767,038
Stock issued for intangible assets, amount	$ 6,000	$ 199	117,774		123,973
Shares cancellation, shares		(762,776,434)
Shares cancellation, amount		$ (1,831)	1,831
Forgiveness of shareholder debt			28,818		28,818
Stock split - 416.7 to 1		$ 412,835	(198,298)	(214,537)
Stock options granted for services			663,307		663,307
Stock and warrants issued for cash, shares		583,334
Stock and warrants issued for cash, amount		$ 583	$ 174,417		$ 175,000
Stock options granted for services, shares			23,825		23,825
Stock options granted for services, amount			$ 1,182,141		$ 1,182,141
Stock issued for services, amount					0
Net loss				(3,004,937)	(3,004,937)
Ending balance, shares at Mar. 31, 2014	6,000,000	414,411,438
Ending balance, amount at Mar. 31, 2014	$ 6,000	$ 414,411	2,043,690	(3,301,404)	(837,303)
Issuance of common stock for cash, shares		79,961,892
Issuance of common stock for cash, amount		$ 79,962	140,038		220,000
Stock issued for intangible assets, shares		220,792,028
Stock issued for intangible assets, amount		$ 220,792	7,683,563		7,904,355
Deemed dividend for intangibles			(7,822,235)		(7,822,235)
Stock options granted for services			815,680		815,680
Stock and warrants issued for cash, shares		2,483,334
Stock and warrants issued for cash, amount		$ 2,483	337,517		340,000
Stock issued for services, shares		16,000,000
Stock issued for services, amount		$ 16,000	780,050		796,050
Stock issued for stock deposits, shares		1,469,000
Stock issued for stock deposits, amount		$ 1,469	145,581		147,050
Stock issued for debt conversion, shares		805,966,265
Stock issued for debt conversion, amount		$ 805,966	(306,280)		499,686
Derivative liability closed to APIC			300,904		300,904
Stock option modification			50,448		50,448
Net loss				(4,133,576)	(4,133,576)
Ending balance, shares at Mar. 31, 2015	6,000,000	1,541,083,957
Ending balance, amount at Mar. 31, 2015	$ 6,000	$ 1,541,083	$ 4,168,956	$ (7,434,980)	$ (1,718,941)

Shareholders Equity (Parentheti

Shareholders Equity (Parenthetical)	12 Months Ended
	Mar. 31, 2015
Statement of Stockholders' Equity [Abstract]
Forward Split	416.7

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the year	$ (4,133,576)	$ (3,004,937)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	473	158
Amortization of debt discount	504,269	0
Change in value of derivative liability	(1,867,621)	0
Derivative expense	(1,809,914)	0
Forgiveness of debt	$ (6,009)	$ 0
Loss on share issuance	$ (30,000)	$ 0
Impairment of intangible asset	$ 82,120	$ 168,973
Stock issued for services	796,050	0
Stock-based compensation	866,128	1,869,273
Changes in operating assets and liabilities:
Increase in prepaid expenses	(6,017)	(1,561)
Increase in accounts payable	729,600	173,972
Increase (decrease) in accrued expenses	(250,399)	451,290
Net Cash Used by Operating Activities	(1,445,068)	(342,832)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of fixed assets	0	(1,419)
Acquisition of intangible assets	0	(45,000)
Net Cash Used by Investing Activities	0	(46,419)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans and interest received (repaid) from/to related parties	(29,933)	40,500
Proceeds from stock deposits	0	147,500
Proceeds from sale of common stock and stock warrants	560,000	175,000
Proceeds from the issuance of convertible note payable	918,506	37,500
Net Cash Provided by Financing Activities	1,448,573	400,050
Net Increase in Cash and Cash Equivalents	3,505	10,799
Cash and cash equivalents, beginning of period	12,387	1,588
Cash and cash equivalents, end of period	15,892	12,387
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	0	342
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Stock deposits reclassified as common stock and stock warrants	147,050	0
Original issue and debt discounts recorded on notes payable	612,827	0
Acquisition of intangibles for stock	82,120	123,973
Debt and interest converted to common stock and contributed capital	$ 499,686	$ 28,818

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2015 and 2014 the Company had $15,892 and $12,387, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company aquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2015 and 2014. As of March 31, 2015, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	12 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of March 31, 2015 and 2014: 2015 2014 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (631 ) (158 ) Property and equipment, net $ 788 $ 1,261 The useful life of the computer equipment is 3 years. Depreciation expense was $473 and $158 for the years ended March 31, 2015 and 2014, respectively .

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of March 31, 2015 and 2014: 2015 2014 Wages and taxes 175,357 151,290 Accrued interest 25,534 0 Consulting 0 300,000 Total accrued expenses $ 200,891 $ 451,290 The Company amended a consulting agreement on May 7, 2014, to grant 2,500,000 shares to a consultant for work performed through March 31, 2014. The shares were valued on the grant date at $300,000 and that amount had been accrued as of March 31, 2014.

Related Party Debt and Transact

Related Party Debt and Transactions	12 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Debt and Transactions	On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. The loan is unsecured and bears 8% interest. The total due was $6,000 as of March 31, 2015. Interest accrued on the 2015 note for the year ended March 31, 2015 was $67. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 3,000,240 shares of common stock at an exercise price of $0.02 per share. The CEO earned $275,000 and $229,167 for the years ended March 31, 2015 and 2014 (respectively) as a result of this agreement, of which, $154,062 and $129,717 has been accrued as of March 31, 2015 and 2014.

Stock Deposits

Stock Deposits	12 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Stock Deposits	The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 1,469,000 shares of common stock in exchange for the deposits. The remaining balance as of March 31, 2015 is $0.

Convertible Note Payable

Convertible Note Payable	12 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Note Payable	On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 2,159,271 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 15,252,347 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 121,442,490 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 131,091,236 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 140,370,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $1,067 as of March 31, 2015. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 179,825,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 18,181,818 shares of common stock leaving a remaining balance of $54,500. Accrued interest was $7,740 as of March 31, 2015. The loan has an unamortized original issue discount of $2,523 as of March 31, 2015. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. On March 10, 2015 the note holder converted $25,200 of the principle into 70,000,000 common shares leaving a remaining balance of $29,800. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $1,273. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $2,622. On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $1,188. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $586. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended March 31, 2015 is $639. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 121,555,062 common shares leaving a remaining balance of $1,898.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the year ending March 31, 2015: $37,500 note dated March 11, 2014; $53,000 note dated April 8, 2014; $42,500 note dated May 21, 2014; $55,000 note dated September 23, 2014; $66,780 note dated August 14, 2014; $58,300 note dated August 14, 2014; $64,500 note dated September 18, 2014; $58,300 note dated March 2, 2015; $61,111 note dated August 13, 2014; $57,895 note dated August 19, 2014; $33,333 note dated December 16, 2014; $27,778 note dated February 25, 2015. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended March 31, 2015, the Company recorded a total change in the fair market value of the derivative liabilities of $1,867,621. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.001 - $0.037, exercise price of $0.0005 - $0.0203, dividend yield of zero, years to maturity of 0.126 – 1.88, a risk free rate of 0.02% - 0.67%, and annualized volatility of 138% - 403%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370. Based on the valuations on the initial valuation dates, the Company recognized debt discounts related to the conversion features totaling $576,370 and a derivative expense of $1,809,914 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of March 31, 2015, unamortized debt discount, including original issue discounts totaling $108,558. The derivative liabilities totaled $217,758 as of March 31, 2015, of which $77,775 related to long-term debt.

Equity Transactions

Equity Transactions	12 Months Ended
	Mar. 31, 2015
Equity Transactions
Equity Transactions	The Company has 37,503,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 82,767,038 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 500,255,434 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares from 90,000,000 to 37,503,000,000. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $ 0.30 $ 0.02 $ 0.02 Exercise price $ 0.50 $ 0.50 $ 0.50 Expected life 1 year 1 year 1 year Volatility 147 % 64 % 65 % Risk-free rate 0.12 % 0.11 % 0.13 % Calculated value $ 10,473 $ 0 $ 0 Fair value allocation of proceeds $ 7,381 $ 0 $ 0 On April 4, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 1,000,000 units at $0.25 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.35 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 700,000 units at $0.043 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 700,000 units at $0.05 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992 The following is a summary of the warrant activity for the years ended March 31, 2015 and 2014: Number of warrants Weighted average exercise price Outstanding, April 1, 2103 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 On May 7, 2014, the Company granted 2,500,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 1,469,000 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 1,000,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 8,000,000 shares of common stock to the CEO and 4,000,000 shares of common stock to the Company’s attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2015, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 500,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Company’s common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Company’s common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 79,961,892 shares of common stock to this investor for total proceeds of $220,000. During the year ended March 31, 2015, the Company received twenty-five conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 550,459 $ 0.0218 October 1, 2014 $ 12,000 648,649 $ 0.0185 October 8, 2014 $ 9,000 505,618 $ 0.0178 October 16, 2014 $ 6,000 454,545 $ 0.0132 October 29, 2014 $ 15,000 1,250,000 $ 0.0120 November 3, 2014 $ 10,000 819,672 $ 0.0122 November 7, 2014 $ 12,000 1,188,119 $ 0.0101 November 19, 2014 $ 18,120 2,831,250 $ 0.0064 December 8, 2014 $ 15,000 3,488,372 $ 0.0043 December 15, 2014 $ 12,000 4,285,714 $ 0.0028 December 26, 2014 $ 17,200 7,478,261 $ 0.0023 February 11, 2015 $ 29,900 74,750,000 $ 0.0004 February 12, 2015 $ 17,333 37,356,055 $ 0.00046 February 13, 2015 $ 17,894 37,280,000 $ 0.00048 February 15, 2015 $ 35,730 73,924,324 $ 0.00048 February 17, 2015 $ 17,003 36,643,945 $ 0.00046 February 23, 2015 $ 20,603 47,090,000 $ 0.00044 February 23, 2015 $ 17,003 36,643,945 $ 0.00046 February 24, 2015 $ 9,488 20,447,291 $ 0.00046 February 26, 2015 $ 42,030 105,075,000 $ 0.0004 February 27, 2015 $ 26,880 56,000,000 $ 0.00048 March 2, 2015 $ 56,402 121,555,062 $ 0.00046 March 9, 2015 $ 33,900 47,518,166 $ 0.00071 March 10, 2015 $ 25,200 70,000,000 $ 0.00036 March 20, 2015 $ 10,000 18,181,818 $ 0.00006 Total $ 498,686 805,966,265 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 47,503,280 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. Effective January 12, 2015, the Company approved the re-pricing of all 67,253,280 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0191984 per share and $0.30 per share, to $0.0017 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 in related stock based compensation expense for the year ending March 31, 2015. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 2 3 , 2014 October 6, 2014 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 Stock price grant date $ 0.02 $ 0.02 $ 0.30 $ 0.12 $ 0.069 $ .0358 Initial Exercise price $ 0.0191984 $ 0.0191984 $ 0.30 $ 0.12 $ 0.069 $ 0.0191984 Modified Exercise price $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 Volatility 76 % 74 % 74 % 73 % 88 % 101 % Risk-free rate 2.94 % 2.71 % 2.65 % 2.56 % 2.53 % 1.04 % Calculated value $ 663,307 $ 23,825 $ 1,182,141 $ 315,772 $ 45,109 $ 454,798 Modified value $ 689,033 $ 24,737 $ 1,188,971 $ 319,750 $ 45,840 $ 467,069 The following is a summary of the option activity for the years ended March 31, 2015 and 2014: Number of options Weighted average |exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0017 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0017 Granted 19,750,000 $0.0017 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0017

Commitments and Contigencies

Commitments and Contigencies	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,600. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. In January 2015, the trial in the Litigation was concluded in the Court. The Court has not rendered a verdict in the Litigation as of the date of this filing. The Company believes the allegations in the complaint are without merit and the Company intends to defend itself in the Litigation. However, the Company has incurred expenses and the diversion of financial resources and management personnel in responding to the complaint. Additionally, an adverse determination against the Company in the Litigation may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, an adverse determination against the Company in the Litigation may require us to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the Company’s affected products and intellectual property rights.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	As of March 31, 2015, the Company had net operating loss carry forwards of approximately $7,220,443 that may be available to reduce future years’ taxable income in varying amounts through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the years ended March 31, 2015 and 2014: 2015 2014 Federal income tax benefit attributable to: Current operations $ 1,405,416 $ 1,021,679 Less: valuation allowance (1,405,416 ) (1,021,679 ) Net provision for Federal income taxes $ 0 $ 0 The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of March 31, 2015 and 2014: March 31, 2015 March 31, 2014 Deferred tax asset attributable to: Net operating loss carryover $ 2,454,951 $ 1,049,535 Less: valuation allowance (2,454,951 ) (1,049,535 ) Net deferred tax asset $ 0 $ 0 Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $7,220,443 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Subsequent Events	On April 6, 2015, the Company approved an amendment to their 2013 Equity Incentive Plan. This amendment increases the reserved common shares for the plan to 390,004,800. On April 16, 2015, in conjunction with the April 6, 2015 amendment, the board approved the issuance of 204,000,250 new options with an exercise price of $0.0008, grant date of April 16, 2015, and term of 5 years. On April 22, 2015, the Company sold 10,037,107 common shares for $5,405 cash, at a per share price of $0.000498. On June 25, 2015, the Company sold 154,245,477 common shares for $10,797 cash, at a per share price of $0.00007. On July 7, 2015, the Company sold 161,942,326 shares of common stock for $11,336 in cash or $0.00007 per share. On July 15, 2015, the Company sold 143,928,240 shares of common stock for $10,075 in cash, or $0.00007 per share. On June 9, 2015, the Company granted 90,000,000 stock warrants to a legal firm for services rendered. The Company issued the following common shares to satisfy the conversion of the following debt subsequent to the March 31, 2015 year end: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 41,111,111 $ 0.00041 April 6, 2015 $ 10,000 20,964,361 $ 0.00048 April 8, 2015 $ 15,309 45,356,111 $ 0.00034 April 8, 2015 $ 20,000 45,454,545 $ 0.00044 April 9, 2015 $ 14,320 32,545,455 $ 0.00044 April 14, 2015 $ 10,000 23,696,682 $ 0.00042 April 16, 2015 $ 1,918 5,300,000 $ 0.00036 April 21, 2015 $ 10,000 25,974,026 $ 0.00039 April 29, 2015 $ 15,000 38,961,039 $ 0.00039 May 4, 2015 $ 5,083 13,146,439 $ 0.00039 May 12, 2015 $ 28,456 90,337,960 $ 0.00031 May 20, 2015 $ 20,199 94,764,514 $ 0.00021 May 20, 015 $ 17,240 78,363,636 $ 0.00022 May 27, 2015 $ 13,568 70,180,137 $ 0.00019 May 29, 2015 $ 15,000 88,235,295 $ 0.00017 June 11, 2015 $ 9,897 94,260,947 $ 0.00010 June 16, 2015 $ 14,100 117,500,000 $ 0.00012 June 16, 2015 $ 13,565 113,041,667 $ 0.00012 June 22, 2015 $ 7,415 123,583,333 $ 0.00006 June 22, 2015 $ 14,384 247,992,413 $ 0.00006 June 23, 2015 $ 7,752 129,200,000 $ 0.00006 Total $ 279,857 1,539,969,671 On May 5, 2015, the Company issued a convertible note payable in the amount of $137,800 including an original issue discount of $7,800. This loan contains a front-end funding of $68,900 and a back-end funding of $68,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. On May 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears a one-time 8% interest rate and is due on May 28, 2016. The loan becomes convertible on November 28, 2015, six months from the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest rate and is due on June 4, 2016. The loan becomes convertible on March 2, 2016, 180 days after the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the two lowest trading price for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. During the subsequent quarter the Company borrowed $13,600 from related parties. The debt bears no interest and is payable at the convenience of the Company. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2015 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2015 and 2014 the Company had $15,892 and $12,387, respectively, of unrestricted cash.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	2015 2014 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (631 ) (158 ) Property and equipment, net $ 788 $ 1,261

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	2015 2014 Wages and taxes 175,357 151,290 Accrued interest 25,534 0 Consulting 0 300,000 Total accrued expenses $ 200,891 $ 451,290

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $ 0.30 $ 0.02 $ 0.02 Exercise price $ 0.50 $ 0.50 $ 0.50 Expected life 1 year 1 year 1 year Volatility 147 % 64 % 65 % Risk-free rate 0.12 % 0.11 % 0.13 % Calculated value $ 10,473 $ 0 $ 0 Fair value allocation of proceeds $ 7,381 $ 0 $ 0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992
Schedule of Warrant Activity	Number of warrants Weighted average exercise price Outstanding, April 1, 2103 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29
Schedule of Conversions of Common Stock	Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 Warrants 83,334 1,000,000 700,000 700,000 Stock price on grant date $ 0.199 $ 0.252 $ 0.037 $ 0.037 Exercise price $ 0.50 $ 0.35 $ 0.15 $ 0.15 Expected life 1 year 3 year 3 year 3 year Volatility 113 % 76 % 119 % 119 % Risk-free rate 0.12 % 0.84 % 0.96 % 0.98 % Calculated value $ 3,181 $ 104,416 $ 12,130 $ 12,102 Fair value allocation of proceeds $ 2,822 $ 73,653 $ 8,637 $ 8,992
Schedule of Value of Options	Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 2 3 , 2014 October 6, 2014 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 Stock price grant date $ 0.02 $ 0.02 $ 0.30 $ 0.12 $ 0.069 $ .0358 Initial Exercise price $ 0.0191984 $ 0.0191984 $ 0.30 $ 0.12 $ 0.069 $ 0.0191984 Modified Exercise price $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 $ 0.0017 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 Volatility 76 % 74 % 74 % 73 % 88 % 101 % Risk-free rate 2.94 % 2.71 % 2.65 % 2.56 % 2.53 % 1.04 % Calculated value $ 663,307 $ 23,825 $ 1,182,141 $ 315,772 $ 45,109 $ 454,798 Modified value $ 689,033 $ 24,737 $ 1,188,971 $ 319,750 $ 45,840 $ 467,069
Schedule of Option Activity	Number of options Weighted average |exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0017 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0017 Granted 19,750,000 $0.0017 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0017

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax	2015 2014 Federal income tax benefit attributable to: Current operations $ 1,405,416 $ 1,021,679 Less: valuation allowance (1,405,416 ) (1,021,679 ) Net provision for Federal income taxes $ 0 $ 0
Schedule of Deferred Tax Asset	March 31, 2015 March 31, 2014 Deferred tax asset attributable to: Net operating loss carryover $ 2,454,951 $ 1,049,535 Less: valuation allowance (2,454,951 ) (1,049,535 ) Net deferred tax asset $ 0 $ 0

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation	Aug. 9, 2010
Common Stock, Shares Authorized | shares	37,503,000,000	37,503,000,000	37,503,000,000	90,000,000
Common Stock, Par Value | $ / shares	$ .001	$ .001	$ 0.001	$ 0.001
Stock split ratio	416.7
Cash and cash equivalent	$ 15,892	$ 12,387
Intangible assets	0
Impairment of intangible asset	$ 82,120	$ 168,973
Reserved common shares | shares	90,004,800
Stock options granted | shares	19,750,000
Computer equipment	3 years
Options granted, number of shares | shares	19,750,000	47,503,280
Options, exercise price | $ / shares	$ .0017
Sale Agmt
Cancellation of loans	$ 28,818
Shares sold by former officers | shares	531,292,500
Asset Assign Agmt
Termination of agreement		$ 20,000
Additional cash required		$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Computer equipment	$ 1,419	$ 1,419
Less: accumulated depreciation	(631)	(158)
Property and equipment, net	$ 788	$ 1,261

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Property And Equipment Details Narrative
Depreciation expense	$ 158	$ 473	$ 158
Computer equipment		3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Impairment of intangible asset	$ 82,120	$ 168,973
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued	220,792,028
Common stock, value	$ 7,904,355
Impaired Assets	0
Impairment of intangible asset	$ 82,120
Consulting Agreement
Date of Agreement		May 7, 2014
Common Stock, shares issued		82,767,038
Series A Preferred Stock, shares issued		6,000,000
Common stock, value		$ 123,973
Series A Preferred Stock, value		45,000
Impaired Assets		$ 0

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Payables and Accruals [Abstract]
Wages and taxes	$ 175,357	$ 151,290
Accrued interest	25,534	0
Consulting	0	300,000
Total accrued expenses	$ 200,891	$ 451,290

Accrued Expenses (Details Narra

Accrued Expenses (Details Narrative) - 12 months ended Mar. 31, 2014 - Consulting Agreement - USD ($)	Total
Agreement date	May 7, 2014
Shares issued to consultant	2,500,000
Share issued, value	$ 300,000

Related Party Debt and Transa32

Related Party Debt and Transactions (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2015
Due to related parties	$ 6,067	$ 36,000	$ 13,600
Loans and interest received (repaid) from/to related parties	(29,933)	40,500
Interest expense, related party	(67)	0
Sale Agmt
Cancellation of loans	28,818
CEO
Loan from related party	5,000	36,000
Repayment of loans to related parties	41,000
Shareholder
Loan from related party	$ 6,000
Interest Rate	8.00%
Interest expense, related party	$ (67)
Employment Agmt
Date of Agreement	Sep. 6, 2013
Term of Agreement	2 years
Annual Compensation	$ 275,000
Options to purchase	3,000,240
Options to purchase, exercise price	$ 0.02
Bonus	$ 68,750
Earnings	275,000	229,167
Accrued Earnings	$ 154,062	$ 129,717

Stock Deposits (Details Narrati

Stock Deposits (Details Narrative) - 12 months ended Mar. 31, 2015 - USD ($)	Total
Notes to Financial Statements
Proceeds from stock deposits	$ 147,050
Stokc issued in exchange for deposits	1,469,000

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument, Converted Amount	$ 499,686	$ 28,818
Convertible Prom Note #1
Date of Agreement	Mar. 11, 2014
Convertible Note	$ 37,500
Interest Rate	8.00%
Due Date	Dec. 13, 2014
Interest Accrued	$ 0
Convertible Note, Balance	0
Debt Instrument, Converted Amount	37,500
Debt Instrument, Interest Accrued, Converted Amount	$ 1,500
Common Stock, shares issued	2,159,271
Convertible Prom Note #2
Date of Agreement	Apr. 8, 2014
Convertible Note	$ 53,000
Interest Rate	8.00%
Due Date	Jan. 14, 2015
Interest Accrued	$ 0
Convertible Note, Balance	0
Debt Instrument, Converted Amount	53,000
Debt Instrument, Interest Accrued, Converted Amount	$ 2,120
Common Stock, shares issued	6,089,041
Convertible Prom Note #3
Date of Agreement	May 21, 2014
Convertible Note	$ 42,500
Interest Rate	8.00%
Due Date	Feb. 23, 2015
Interest Accrued	$ 0
Convertible Note, Balance	0
Debt Instrument, Converted Amount	42,500
Debt Instrument, Interest Accrued, Converted Amount	$ 1,700
Common Stock, shares issued	15,252,347
Convertible Prom Note #4
Date of Agreement	Aug. 14, 2014
Convertible Note	$ 66,780
Interest Rate	8.00%
Due Date	Aug. 14, 2015
Interest Accrued	$ 0
Convertible Note, Balance	0
Original Issue Discount	3,380
Debt Instrument, Converted Amount	66,780
Debt Instrument, Interest Accrued, Converted Amount	$ 2,850
Common Stock, shares issued	121,442,490
Convertible Prom Note #5
Date of Agreement	Aug. 14, 2014
Convertible Note	$ 58,300
Interest Rate	8.00%
Due Date	Aug. 14, 2015
Interest Accrued	$ 0
Convertible Note, Balance	0
Original Issue Discount	3,300
Debt Instrument, Converted Amount	58,300
Debt Instrument, Interest Accrued, Converted Amount	$ 2,527
Common Stock, shares issued	131,091,236
Convertible Prom Note #6
Date of Agreement	Aug. 13, 2014
Convertible Note	$ 61,111
Interest Rate	12.00%
Due Date	Aug. 14, 2016
Interest Accrued	$ 1,067
Convertible Note, Balance	0
Original Issue Discount	5,500
Debt Instrument, Converted Amount	61,111
Debt Instrument, Interest Accrued, Converted Amount	$ 6,266
Common Stock, shares issued	140,370,000
Convertible Prom Note #7
Date of Agreement	Aug. 19, 2014
Convertible Note	$ 57,895
Interest Rate	12.00%
Due Date	Aug. 19, 2016
Interest Accrued	$ 0
Convertible Note, Balance	0
Original Issue Discount	2,895
Debt Instrument, Converted Amount	57,895
Debt Instrument, Interest Accrued, Converted Amount	$ 14,035
Common Stock, shares issued	179,825,000
Convertible Prom Note #8
Date of Agreement	Sep. 18, 2014
Convertible Note	$ 64,500
Interest Rate	12.00%
Due Date	Sep. 18, 2015
Interest Accrued	$ 7,740
Convertible Note, Balance	54,500
Original Issue Discount	5,500
Original Issue Discount, unamortized	2,523
Debt Instrument, Converted Amount	$ 10,000
Common Stock, shares issued	18,181,818
Convertible Prom Note #9
Date of Agreement	Sep. 23, 2014
Convertible Note	$ 55,000
Interest Rate	8.00%
Due Date	Jun. 23, 2015
Interest Accrued	$ 2,162
Convertible Note, Balance	29,800
Debt Instrument, Converted Amount	$ 25,200
Common Stock, shares issued	70,000,000
Convertible Prom Note #10
Date of Agreement	Oct. 6, 2014
Convertible Note	$ 33,000
Interest Rate	8.00%
Due Date	Jul. 6, 2015
Interest Accrued	$ 1,273
Convertible Prom Note #11
Date of Agreement	Nov. 6, 2014
Convertible Note	$ 55,000
Interest Rate	12.00%
Due Date	May 6, 2015
Interest Accrued	$ 2,622
Convertible Prom Note #12
Date of Agreement	Nov. 25, 2014
Convertible Note	$ 43,000
Interest Rate	8.00%
Due Date	Aug. 28, 2015
Interest Accrued	$ 1,188
Convertible Prom Note #13
Date of Agreement	Dec. 16, 2014
Convertible Note	$ 33,333
Interest Rate	12.00%
Due Date	Dec. 16, 2016
Interest Accrued	$ 4,000
Original Issue Discount	3,333
Original Issue Discount, unamortized	$ 2,854
Convertible Prom Note #14
Date of Agreement	Jan. 9, 2015
Convertible Note	$ 33,000
Interest Rate	8.00%
Due Date	Oct. 13, 2015
Interest Accrued	$ 586
Convertible Prom Note #15
Date of Agreement	Feb. 5, 2015
Convertible Note	$ 54,000
Interest Rate	8.00%
Due Date	Nov. 9, 2015
Interest Accrued	$ 639
Convertible Prom Note #16
Date of Agreement	Feb. 17, 2015
Convertible Note	$ 66,780
Interest Rate	8.00%
Due Date	Aug. 14, 2015
Interest Accrued	$ 615
Original Issue Discount	6,780
Original Issue Discount, unamortized	$ 2,835
Convertible Prom Note #17
Date of Agreement	Feb. 25, 2015
Convertible Note	$ 27,778
Interest Rate	12.00%
Due Date	Feb. 25, 2017
Interest Accrued	$ 3,333
Original Issue Discount, unamortized	$ 2,648
Convertible Prom Note #18
Date of Agreement	Mar. 9, 2015
Convertible Note	$ 55,000
Interest Rate	8.00%
Due Date	Dec. 9, 2015
Interest Accrued	$ 265
Convertible Prom Note #19
Date of Agreement	Mar. 26, 2015
Convertible Note	$ 29,680
Interest Rate	8.00%
Due Date	Mar. 23, 2016
Interest Accrued	$ 32
Original Issue Discount	1,680
Original Issue Discount, unamortized	$ 1,653
Convertible Prom Note #20
Date of Agreement	Mar. 2, 2015
Convertible Note	$ 58,300
Interest Rate	8.00%
Due Date	Aug. 14, 2015
Interest Accrued	$ 12
Convertible Note, Balance	1,898
Original Issue Discount	3,300
Original Issue Discount, unamortized	107
Debt Instrument, Converted Amount	$ 56,402
Common Stock, shares issued	121,555,062

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Notes to Financial Statements
Change in value of derivative liability	$ (1,867,621)	$ 0
Derivative expense	(1,809,914)	0
Derivative liabilities	$ 77,775	$ 0

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - 12 months ended Mar. 31, 2015 - USD ($)	Total
Warrant #1
Date	Oct. 29, 2013
Warrants	$ 250,000
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	147.00%
Risk-free rate	0.12%
Calculated value	$ 10,473
Fair value allocation of proceeds	$ 7,381
Warrant #2
Date	Dec. 11, 2013
Warrants	$ 250,000
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	64.00%
Risk-free rate	0.11%
Calculated value	$ 0
Fair value allocation of proceeds	$ 0
Warrant #3
Date	Mar. 10, 2014
Warrants	$ 83,334
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	65.00%
Risk-free rate	0.13%
Calculated value	$ 0
Fair value allocation of proceeds	$ 0
Warrant #4
Date	Apr. 4, 2014
Warrants	$ 83,334
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	113.00%
Risk-free rate	0.12%
Calculated value	$ 3,181
Fair value allocation of proceeds	$ 3,181
Warrant #5
Date	Apr. 15, 2014
Warrants	$ 1,000,000
Stock price on grant date	$ 0.25
Exercise price	$ 0.35
Expected life	3 years
Volatility	76.00%
Risk-free rate	0.84%
Calculated value	$ 104,416
Fair value allocation of proceeds	$ 104,416
Warrant #6
Date	Jul. 10, 2014
Warrants	$ 700,000
Stock price on grant date	$ 0.037
Exercise price	$ 0.15
Expected life	3 years
Volatility	119.00%
Risk-free rate	0.96%
Calculated value	$ 12,130
Fair value allocation of proceeds	$ 8,637
Warrant #7
Date	Jul. 29, 2014
Warrants	$ 700,000
Stock price on grant date	$ 0.037
Exercise price	$ 0.15
Expected life	3 years
Volatility	119.00%
Risk-free rate	0.98%
Calculated value	$ 12,102
Fair value allocation of proceeds	$ 8,992

Equity Transactions - Schedul37

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	583,334	583,334
Beginning Balance, Average Exercise Price	$ 0.50	$ .50
Issued, Warrants	2,483,334
Issued, Average Exercise Price	$ 0.24
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	3,066,668	583,334
Ending Balance, Average Exercise Price	$ 0.29	$ 0.50

Equity Transactions - Schedul38

Equity Transactions - Schedule of Value of Options (Details) - 12 months ended Mar. 31, 2015 - USD ($)	Total
Stock Option 1
Date of Issuance	Sep. 6, 2013
Options	41,003,280
Stock price on grant date	$ 0.02
Exercise price	$ 0.0191984
Expected life	10 years
Volatility	76.00%
Risk-free rate	2.94%
Calculated value	$ 663,307
Stock Option 2
Date of Issuance	Feb. 7, 2014
Options	1,500,000
Stock price on grant date	$ 0.02
Exercise price	$ 0.0191984
Expected life	10 years
Volatility	74.00%
Risk-free rate	2.71%
Calculated value	$ 23,825
Stock Option 3
Date of Issuance	Mar. 14, 2014
Options	5,000,000
Stock price on grant date	$ 0.30
Exercise price	$ 0.30
Expected life	10 years
Volatility	74.00%
Risk-free rate	2.65%
Calculated value	$ 1,182,141
Stock Option 4
Date of Issuance	May 7, 2014
Options	3,500,000
Stock price on grant date	$ .12
Exercise price	$ .12
Expected life	10 years
Volatility	73.00%
Risk-free rate	2.56%
Calculated value	$ 315,772
Stock Option 5
Date of Issuance	Jul. 23, 2014
Options	750,000
Stock price on grant date	$ .069
Exercise price	$ .069
Expected life	10 years
Volatility	88.00%
Risk-free rate	2.53%
Calculated value	$ 45,109
Stock Option 6
Date of Issuance	Oct. 6, 2014
Options	15,500,000
Stock price on grant date	$ .0358
Exercise price	$ .0191984
Expected life	5 years
Volatility	101.00%
Risk-free rate	1.04%
Calculated value	$ 454,798

Equity Transactions - Schedul39

Equity Transactions - Schedule of Option Activity (Details) - shares	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	47,503,280	47,503,280
Beginning Balance, weighted average exercise price	0.0017	0.0017
Options granted, number of shares	19,750,000	47,503,280
Options granted, weighted average exercise price	.0017
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	67,253,280	47,503,280
Ending Balance, weighted average exercise price	0.0017	0.0017

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	12 Months Ended
	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000	37,503,000,000	90,000,000
Common Stock, Par Value | $ / shares	$ .001	$ .001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par Value | $ / shares	$ .001	$ .001
Series A Preferred Stock, Designated					6,000,000
Common Stock, Issued	1,541,083,957	414,411,438
Preferred Stock, Issued	6,000,000	6,000,000
Stock split ratio	416.7
Options granted, number of shares	19,750,000	47,503,280
Shares issued for services, value | $	$ 796,050	$ 0
Debt Instrument, Converted Amount | $	$ 499,686	$ 28,818
Warrant #6
Common Stock, shares issued	700,000
Date	Jul. 10, 2014
Warrants | $	$ 700,000
Stock price on grant date | $ / shares	$ 0.043
Exercise price | $ / shares	$ 0.15
Expected life	3 years
Warrant #7
Common Stock, shares issued	700,000
Date	Jul. 29, 2014
Warrants | $	$ 700,000
Stock price on grant date | $ / shares	$ 0.05
Exercise price | $ / shares	$ 0.15
Expected life	3 years
Debt Conversion #1
Date of Agreement	Sep. 22, 2014
Common Stock, shares issued	550,459
Common Stock, price per share | $ / shares	$ 0.0218
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #2
Date of Agreement	Oct. 1, 2014
Common Stock, shares issued	648,649
Common Stock, price per share | $ / shares	$ 0.0185
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #3
Date of Agreement	Oct. 8, 2014
Common Stock, shares issued	505,618
Common Stock, price per share | $ / shares	$ 0.0178
Debt Instrument, Converted Amount | $	$ 9,000
Debt Conversion #4
Date of Agreement	Oct. 16, 2014
Common Stock, shares issued	454,545
Common Stock, price per share | $ / shares	$ 0.0132
Debt Instrument, Converted Amount | $	$ 6,000
Debt Conversion #5
Date of Agreement	Oct. 29, 2014
Common Stock, shares issued	1,250,000
Common Stock, price per share | $ / shares	$ 0.0120
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #6
Date of Agreement	Nov. 3, 2014
Common Stock, shares issued	819,672
Common Stock, price per share | $ / shares	$ 0.0122
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #7
Date of Agreement	Nov. 7, 2014
Common Stock, shares issued	1,188,119
Common Stock, price per share | $ / shares	$ 0.0101
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #8
Date of Agreement	Nov. 19, 2014
Common Stock, shares issued	2,831,250
Common Stock, price per share | $ / shares	$ 0.0064
Debt Instrument, Converted Amount | $	$ 18,120
Debt Conversion #9
Date of Agreement	Dec. 8, 2014
Common Stock, shares issued	3,488,372
Common Stock, price per share | $ / shares	$ 0.0043
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #10
Date of Agreement	Dec. 15, 2014
Common Stock, shares issued	4,285,714
Common Stock, price per share | $ / shares	$ 0.0028
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #11
Date of Agreement	Dec. 26, 2014
Common Stock, shares issued	7,478,261
Common Stock, price per share | $ / shares	$ 0.0023
Debt Instrument, Converted Amount | $	$ 17,200
Debt Conversion #12
Date of Agreement	Feb. 11, 2015
Common Stock, shares issued	74,750,000
Common Stock, price per share | $ / shares	$ 0.0004
Debt Instrument, Converted Amount | $	$ 29,900
Debt Conversion #13
Date of Agreement	Feb. 12, 2015
Common Stock, shares issued	37,356,055
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,333
Debt Conversion #14
Date of Agreement	Feb. 15, 2015
Common Stock, shares issued	73,924,324
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 35,730
Legal Services
Shares issued for services	1,000,000
Shares issued for services, value | $	$ 30,000
Date	Jul. 1, 2014
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued	220,792,028
Shares Issued, Value | $	$ 7,904,355
Asset Assign Agmt
Date of Agreement	Jul. 18, 2015
Common Stock, shares issued	82,767,038
Series A Preferred Stock, shares issued	6,000,000
Shares Issued, Value | $	$ 123,973
Sale Agmt
Shares agreed to cancel	262,521,000
Shares returned to treasury	500,255,434
Date of Agreement	Jul. 19, 2013
Consultant
Shares issued for services	2,500,000
Shares issued for services, value | $	$ 300,000
Date	May 7, 2014
Stock Deposits
Common Stock, shares issued	1,469,000
Shares Issued, Value | $	$ 147,050
Date	Jun. 16, 2014
Warrant #1
Common Stock, shares issued	250,000
Date	Oct. 29, 2013
Warrants | $	$ 250,000
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #2
Common Stock, shares issued	250,000
Date	Dec. 11, 2013
Warrants | $	$ 250,000
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #3
Common Stock, shares issued	83,334
Date	Mar. 10, 2014
Warrants | $	$ 83,334
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #4
Common Stock, shares issued	83,334
Date	Apr. 4, 2014
Warrants | $	$ 83,334
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #5
Common Stock, shares issued	1,000,000
Date	Apr. 15, 2014
Warrants | $	$ 1,000,000
Stock price on grant date | $ / shares	$ 0.25
Exercise price | $ / shares	$ 0.35
Expected life	3 years
CEO
Date of Agreement	Oct. 6, 2014
Shares issued for services	8,000,000
Attorney
Date of Agreement	Oct. 6, 2014
Shares issued for services	4,000,000
Vendor
Shares issued for services	500,000
Shares issued for services, value | $	$ 6,450
Investment Agmt
Date of Agreement	Aug. 13, 2014
Shares issued for services	79,961,892
Shares issued for services, value | $	$ 220,000
Debt Conversion #15
Date of Agreement	Feb. 13, 2015
Common Stock, shares issued	37,280,000
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 17,894
Debt Conversion #16
Date of Agreement	Feb. 17, 2015
Common Stock, shares issued	36,643,945
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,003
Debt Conversion #17
Date of Agreement	Feb. 23, 2015
Common Stock, shares issued	47,090,000
Common Stock, price per share | $ / shares	$ 0.00044
Debt Instrument, Converted Amount | $	$ 20,603
Debt Conversion #18
Date of Agreement	Feb. 23, 2015
Common Stock, shares issued	36,643,945
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,003
Debt Conversion #19
Date of Agreement	Feb. 24, 2015
Common Stock, shares issued	20,447,291
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 9,488
Debt Conversion #20
Date of Agreement	Feb. 26, 2015
Common Stock, shares issued	105,075,000
Common Stock, price per share | $ / shares	$ 0.0004
Debt Instrument, Converted Amount | $	$ 42,030
Debt Conversion #21
Date of Agreement	Feb. 27, 2015
Common Stock, shares issued	56,000,000
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 26,880
Debt Conversion #22
Date of Agreement	Mar. 2, 2015
Common Stock, shares issued	121,555,062
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 56,402
Debt Conversion #23
Date of Agreement	Mar. 9, 2015
Common Stock, shares issued	47,518,166
Common Stock, price per share | $ / shares	$ 0.00071
Debt Instrument, Converted Amount | $	$ 33,900
Debt Conversion #24
Date of Agreement	Mar. 10, 2015
Common Stock, shares issued	70,000,000
Common Stock, price per share | $ / shares	$ 0.00036
Debt Instrument, Converted Amount | $	$ 25,200
Debt Conversion #25
Date of Agreement	Mar. 20, 2015
Common Stock, shares issued	18,181,818
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 10,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Mar. 31, 2015USD ($)
Accounting Policies [Abstract]
Monthly Rent	$ 2,600

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Federal income tax benefit attributable to:
Current operations	$ 1,405,416	$ 1,021,679
Less: valuation allowance	(1,405,416)	(1,021,679)
Net provision for Federal income taxes	$ 0	$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,454,951	$ 1,049,535
Less: valuation allowance	(2,454,951)	(1,049,535)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - Mar. 31, 2015 - USD ($)	Total
Income Tax Disclosure [Abstract]
Net Operating Loss Carry-Forwards	$ 7,220,443
Operating Loss Carry-Forwards Expiration Date	Jan. 1, 2033
Effective Tax Rate	34.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
Issued, Warrants				2,483,334
Common Stock, value				$ 220,000
Debt Instrument, Converted Amount				$ 499,686	$ 28,818
Reserved common shares		90,004,800		90,004,800
Due to related parties	$ 13,600	$ 6,067		$ 6,067	$ 36,000
Debt Conversion #26
Common Stock, shares issued	41,111,111
Common Stock, price per share	$ 0.00041
Date of Agreement	Apr. 1, 2015
Debt Instrument, Converted Amount	$ 16,650
Debt Conversion #27
Common Stock, shares issued	20,964,361
Common Stock, price per share	$ 0.00048
Date of Agreement	Apr. 6, 2015
Debt Instrument, Converted Amount	$ 10,000
Debt Conversion #28
Common Stock, shares issued	45,356,111
Common Stock, price per share	$ 0.00034
Date of Agreement	Apr. 8, 2015
Debt Instrument, Converted Amount	$ 15,309
Debt Conversion #43
Common Stock, shares issued		45,454,545
Common Stock, price per share		$ 0.00044
Date of Agreement		Apr. 8, 2015
Debt Instrument, Converted Amount		$ 20,000
Debt Conversion #29
Common Stock, shares issued	32,545,455
Common Stock, price per share	$ 0.00044
Date of Agreement	Apr. 9, 2015
Debt Instrument, Converted Amount	$ 14,320
Debt Conversion #30
Common Stock, shares issued	23,696,682
Common Stock, price per share	$ 0.00042
Date of Agreement	Apr. 14, 2015
Debt Instrument, Converted Amount	$ 10,000
Debt Conversion #31
Common Stock, shares issued	5,300,000
Common Stock, price per share	$ 0.00036
Date of Agreement	Apr. 16, 2015
Debt Instrument, Converted Amount	$ 1,918
Debt Conversion #32
Common Stock, shares issued	25,974,026
Common Stock, price per share	$ 0.00036
Date of Agreement	Apr. 21, 2015
Debt Instrument, Converted Amount	$ 10,000
Debt Conversion #33
Common Stock, shares issued	38,961,039
Common Stock, price per share	$ 0.00039
Date of Agreement	Apr. 29, 2015
Debt Instrument, Converted Amount	$ 15,000
Debt Conversion #34
Common Stock, shares issued	13,146,439
Common Stock, price per share	$ 0.00039
Date of Agreement	May 4, 2015
Debt Instrument, Converted Amount	$ 5,083
Debt Conversion #35
Common Stock, shares issued	90,337,960
Common Stock, price per share	$ 0.00031
Date of Agreement	May 12, 2015
Debt Instrument, Converted Amount	$ 28,456
Debt Conversion #36
Common Stock, shares issued	94,764,514
Common Stock, price per share	$ 0.00021
Date of Agreement	May 20, 2015
Debt Instrument, Converted Amount	$ 20,199
Debt Conversion #37
Common Stock, shares issued	78,363,636
Common Stock, price per share	$ 0.00022
Date of Agreement	May 20, 2015
Debt Instrument, Converted Amount	$ 17,240
Debt Conversion #38
Common Stock, shares issued	70,180,137
Common Stock, price per share	$ 0.00019
Date of Agreement	May 27, 2015
Debt Instrument, Converted Amount	$ 13,568
Debt Conversion #39
Common Stock, shares issued	88,235,295
Common Stock, price per share	$ 0.00017
Date of Agreement	May 29, 2015
Debt Instrument, Converted Amount	$ 15,000
Debt Conversion #40
Common Stock, shares issued	94,260,947
Common Stock, price per share	$ 0.00010
Date of Agreement	Jun. 11, 2015
Debt Instrument, Converted Amount	$ 9,897
Debt Conversion #41
Common Stock, shares issued	117,500,000
Common Stock, price per share	$ 0.00012
Date of Agreement	Jun. 16, 2015
Debt Instrument, Converted Amount	$ 14,100
Debt Conversion #42
Common Stock, shares issued	113,041,667
Common Stock, price per share	$ 0.00012
Date of Agreement	Jun. 16, 2015
Debt Instrument, Converted Amount	$ 13,565
Debt Conversion #44
Common Stock, shares issued		123,583,333
Common Stock, price per share		$ 0.00006
Date of Agreement		Jun. 22, 2015
Debt Instrument, Converted Amount		$ 7,415
Debt Conversion #45
Common Stock, shares issued		247,992,413
Common Stock, price per share		$ 0.00006
Date of Agreement		Jun. 22, 2015
Debt Instrument, Converted Amount		$ 14,384
Debt Conversion #46
Common Stock, shares issued		129,200,000
Common Stock, price per share		$ 0.00006
Date of Agreement		Jun. 23, 2015
Debt Instrument, Converted Amount		$ 7,752
Sale of Stock #3
Date of Issuance			Jul. 7, 2015
Common Stock, shares issued			161,942,326
Common Stock, price per share			$ 0.00007
Common Stock, value			$ 11,336
Sale of Stock #4
Date of Issuance			Jul. 15, 2015
Common Stock, shares issued			143,928,240
Common Stock, price per share			$ 0.00007
Common Stock, value			$ 10,075
Convertible Prom Note #21
Date of Agreement		May 5, 2015
Convertible Note		$ 137,800
Interest Rate		8.00%
Due date		May 5, 2016
Original Issue Discount		780000.00%
Convertible Prom Note #22
Date of Agreement		May 6, 2015
Convertible Note		$ 10,500
Interest Rate		8.00%
Due date		Feb. 8, 2016
Convertible Prom Note #23
Date of Agreement		May 28, 2015
Convertible Note		$ 15,000
Interest Rate		8.00%
Due date		May 28, 2016
Convertible Prom Note #24
Date of Agreement		Sep. 4, 2015
Convertible Note		$ 19,000
Interest Rate		8.00%
Due date		Jun. 4, 2016
2013 Stock Option Plan
Date of Agreement				Apr. 6, 2015
Reserved common shares		390,004,800		390,004,800
2013 Stock Option Plan Amendment
Date of Issuance				Apr. 16, 2015
Options, Granted				204,000,250
Options, Term				5 years
Exercise Price				$ 0.0008
Sale of Stock #1
Date of Issuance				Apr. 22, 2015
Common Stock, shares issued				10,037,107
Common Stock, price per share				$ 0.000498
Common Stock, value				$ 5,405
Sale of Stock #2
Date of Issuance				Jun. 25, 2015
Common Stock, shares issued				154,245,477
Common Stock, price per share				$ 0.00007
Common Stock, value				$ 10,797
Grant of Stock
Date of Issuance				Jun. 9, 2015
Common Stock, shares issued				90,000,000